Patrick Flume to Pseudomonas Infections
This is a "connection" page, showing publications Patrick Flume has written about Pseudomonas Infections.
Connection Strength
3.938
-
Impact of a Reduction in Susceptibility Testing for Pseudomonas aeruginosa in a Cystic Fibrosis Program. Am J Respir Crit Care Med. 2020 01 01; 201(1):114-116.
Score: 0.621
-
Continuous alternating inhaled antibiotics for chronic pseudomonal infection in cystic fibrosis. J Cyst Fibros. 2016 11; 15(6):809-815.
Score: 0.483
-
A phase 3, open-label, randomized trial to evaluate the safety and efficacy of levofloxacin inhalation solution (APT-1026) versus tobramycin inhalation solution in stable cystic fibrosis patients. J Cyst Fibros. 2015 Jul; 14(4):507-14.
Score: 0.440
-
Applying clinical outcome variables to appropriate aerosolized antibiotics for the treatment of patients with cystic fibrosis. Respir Med. 2011 Dec; 105 Suppl 2:S18-23.
Score: 0.354
-
Antipseudomonal treatment decisions during CF exacerbation management. J Cyst Fibros. 2022 09; 21(5):753-758.
Score: 0.182
-
Management of chronic Pseudomonas aeruginosa infection with inhaled levofloxacin in people with cystic fibrosis. Future Microbiol. 2021 09; 16:1087-1104.
Score: 0.174
-
Antimicrobial resistance: Concerns of healthcare providers and people with CF. J Cyst Fibros. 2021 05; 20(3):407-412.
Score: 0.160
-
Reconciling Antimicrobial Susceptibility Testing and Clinical Response in Antimicrobial Treatment of Chronic Cystic Fibrosis Lung Infections. Clin Infect Dis. 2019 10 30; 69(10):1812-1816.
Score: 0.153
-
Developing Inhaled Antibiotics in Cystic Fibrosis: Current Challenges and Opportunities. Ann Am Thorac Soc. 2019 05; 16(5):534-539.
Score: 0.148
-
Standardized Treatment of Pulmonary Exacerbations (STOP) study: Observations at the initiation of intravenous antibiotics for cystic fibrosis pulmonary exacerbations. J Cyst Fibros. 2017 Sep; 16(5):592-599.
Score: 0.129
-
Safety and efficacy of prolonged levofloxacin inhalation solution (APT-1026) treatment for cystic fibrosis and chronic Pseudomonas aeruginosa airway infection. J Cyst Fibros. 2016 09; 15(5):634-40.
Score: 0.119
-
A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation solution (APT-1026) in stable cystic fibrosis patients. J Cyst Fibros. 2016 07; 15(4):495-502.
Score: 0.118
-
One-year safety and efficacy of tobramycin powder for inhalation in patients with cystic fibrosis. Pediatr Pulmonol. 2016 Apr; 51(4):372-8.
Score: 0.117
-
Clinical applications of pulmonary delivery of antibiotics. Adv Drug Deliv Rev. 2015 May; 85:1-6.
Score: 0.108
-
Infectious complications of lung transplantation. Impact of cystic fibrosis. Am J Respir Crit Care Med. 1994 Jun; 149(6):1601-7.
Score: 0.105
-
Treatment of lung infection in patients with cystic fibrosis: current and future strategies. J Cyst Fibros. 2012 Dec; 11(6):461-79.
Score: 0.095
-
Aerosolized antibiotic therapy for chronic cystic fibrosis airway infections: continuous or intermittent? Respir Med. 2011 Dec; 105 Suppl 2:S9-17.
Score: 0.089
-
Levofloxacin inhalation solution (MP-376) in patients with cystic fibrosis with Pseudomonas aeruginosa. Am J Respir Crit Care Med. 2011 Jun 01; 183(11):1510-6.
Score: 0.084
-
Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial. J Cyst Fibros. 2011 Jan; 10(1):54-61.
Score: 0.082
-
Update in cystic fibrosis 2009. Am J Respir Crit Care Med. 2010 Mar 15; 181(6):539-44.
Score: 0.079
-
Treatment options for cystic fibrosis: case study and panel discussion. Pharmacotherapy. 2002 Mar; 22(3 Pt 2):86S-87S.
Score: 0.045
-
Transmissibility of Pseudomonas cepacia infection in clinic patients and lung-transplant recipients with cystic fibrosis. N Engl J Med. 1994 Oct 13; 331(15):981-7.
Score: 0.027
-
Lung transplantation for mechanically ventilated patients. J Heart Lung Transplant. 1994 Jan-Feb; 13(1 Pt 1):15-21; discussion 22-3.
Score: 0.026